Helixmith Co., Ltd (KOSDAQ:084990)
South Korea · Delayed Price · Currency is KRW 3,735.00
+35.00 (0.95%)
Nov 2, 2026, 3:30 PM KST
Helixmith Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,420 | 2,598 | 4,974 | 4,202 | 2,800 | 2,316 |
Revenue Growth | -51.40% | -47.77% | 18.38% | 50.08% | 20.87% | -45.48% |
Gross Profit Gross Profit Growth | 1,214 | 925.31 | 2,126 | 2,101 | -111.34 | 1,063 |
Operating Income Operating Income Growth | -9,421 | -9,888 | -17,940 | -35,245 | -52,579 | -48,518 |
Net Income Net Income Growth | -1,606 | -434.92 | -15,471 | -64,088 | -43,538 | -50,938 |
Earnings Per Share EPS Growth | -34.87 | -9.45 | -329.24 | -1544.00 | -1156.06 | -1352.58 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Research and Development Projects, Etc. Pharmaceutical Research and Development Projects, Etc. Growth | 2,623 | 3,068 | 6,907 | 8,929 | 14,362 | 10,568 |
Consolidation Adjustments Consolidation Adjustments Growth | - | -469.77 | -1,933 | -4,727 | -11,562 | -8,251 |
Total Total Growth | 2,420 | 2,598 | 4,974 | 4,202 | 2,800 | 2,316 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 53,429 | 81,704 | 76,110 | 113,976 | 103,958 | 157,894 |
Total Debt Total Debt Growth | 29.34 | 40.89 | 211.13 | 20,228 | 20,571 | 32,477 |
Net Cash (Debt) Net Cash Growth | 53,400 | 81,663 | 75,899 | 93,749 | 83,388 | 125,417 |
Net Cash Growth | -34.46% | 7.60% | -19.04% | 12.43% | -33.51% | -30.64% |
Net Cash Per Share Net Cash Per Share Growth | 1159.68 | 1773.48 | 1615.17 | 2258.22 | 2214.17 | 3330.28 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -7,105 | -6,898 | -16,717 | -25,888 | -40,741 | -37,294 |
Capital Expenditures CapEx Growth | -207.68 | -212.68 | -429.85 | -254.87 | -4,036 | -11,714 |
Free Cash Flow Free Cash Flow Growth | -7,313 | -7,111 | -17,147 | -26,143 | -44,777 | -49,008 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 50.16% | 35.61% | 42.73% | 50.01% | -3.98% | 45.91% |
Operating Margin | -389.34% | -380.57% | -360.68% | -838.85% | -1878.09% | -2094.70% |
Pretax Margin | -67.41% | -17.71% | -311.35% | -1529.90% | -1536.19% | -2923.49% |
Profit Margin | -66.36% | -16.74% | -311.05% | -1525.33% | -1555.16% | -2199.16% |
FCF Margin | -302.20% | -273.70% | -344.74% | -622.20% | -1599.39% | -2115.83% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 71.07 | 110.24 | 25.00 | 61.02 | 141.85 | 369.08 |